Clinical Research Directory
Browse clinical research sites, groups, and studies.
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Summary
The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.
Official title: Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Adults With Solid Tumors.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
213
Start Date
2023-04-25
Completion Date
2025-09
Last Updated
2025-04-16
Healthy Volunteers
No
Conditions
Interventions
Hetrombopag
Hetrombopag
Hetrombopag plus Placebo
Hetrombopag plus Placebo
Placebo
Placebo
Locations (1)
Hematology Tumor Research Center of Harbin First Hospital
Haerbin, Heilongjiang, China